The Preventive Effect of Helicobacter Pylori Eradication on the Development of Gastric Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2014 by Showa Inan General Hospital
Information provided by (Responsible Party):
Akira Horiuchi, Showa Inan General Hospital Identifier:
First received: January 8, 2008
Last updated: November 12, 2014
Last verified: November 2014

Recently, the preventive effect of Helicobacter pylori (Hp) eradication treatment on the incidence of gastric cancer has been reported. By Hp eradication treatment being performed for Hp-infected people in Iijima town, we will evaluate whether the incidence of gastric cancer and/or the medical care cost can be reduced as compared with those in the previous years.

Helicobacter Pylori
Gastric Cancer
Medical Care Cost

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Effect of Helicobacter Pylori Eradication on the Development of Gastric Cancer and the Medical Care Cost in Iijima Town

Resource links provided by NLM:

Further study details as provided by Showa Inan General Hospital:

Primary Outcome Measures:
  • the annual incidence of gastric cancer in Iijima town [ Time Frame: 10 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The annual medical care cost in Iijima town [ Time Frame: 10 years ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA


Estimated Enrollment: 3000
Study Start Date: September 2007
Estimated Study Completion Date: August 2017
Estimated Primary Completion Date: August 2017 (Final data collection date for primary outcome measure)
HP eradication group
No eradication group
No Hp group


Ages Eligible for Study:   19 Years to 69 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

People who live in Iijima town


Inclusion Criteria:

  • People who live in Iijima town at their age of 19 to 69 years
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00596401

Contact: Akira Horiuchi, M.D. 81265822121 ext 3012

Showa Inan General hospital Recruiting
Komagane, Nagano, Japan, 399-4191
Contact: Akira Horiuchi, M.D.    81265822121 ext 3012   
Principal Investigator: Akira Horiuchi, M.D.         
Sponsors and Collaborators
Showa Inan General Hospital
Study Director: Akira Horiuchi, M.D. Showa Inan General Hospital
  More Information

No publications provided

Responsible Party: Akira Horiuchi, Digestive Disease Center, Showa Inan General Hospital Identifier: NCT00596401     History of Changes
Other Study ID Numbers: sihp20076
Study First Received: January 8, 2008
Last Updated: November 12, 2014
Health Authority: Japan: Ministry of Health, Labor and Welfare

Additional relevant MeSH terms:
Stomach Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Neoplasms by Site
Stomach Diseases processed this record on March 26, 2015